We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+4.83%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.91%
AUM
$46B
AUM Growth
+$2.18B
(+5%)
Cap. Flow
+$425M
Cap. Flow
% of AUM
0.92%
Top 10 Holdings %
Top 10 Hldgs %
15.17%
Holding
2,954
New
28
Increased
2,252
Reduced
604
Closed
50
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
DuPont de Nemours
DD
|
+$128M |
| 2 |
Baker Hughes
BKR
|
+$26.7M |
| 3 |
IQVIA
IQV
|
+$14.5M |
| 4 |
Oneok
OKE
|
+$14.3M |
| 5 |
Berkshire Hathaway Class B
BRK.B
|
+$11.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
DD
Du Pont De Nemours E I
DD
|
+$114M |
| 2 |
RAI
Reynolds American Inc
RAI
|
+$88.6M |
| 3 |
BHI
Baker Hughes
BHI
|
+$41.6M |
| 4 |
WFM
Whole Foods Market Inc
WFM
|
+$26.7M |
| 5 |
UnitedHealth
UNH
|
+$22.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 16.64% |
| 2 | Technology | 15.8% |
| 3 | Healthcare | 13.57% |
| 4 | Industrials | 10.87% |
| 5 | Consumer Discretionary | 9.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CLSD
2751
DELISTED
Clearside Biomedical
CLSD
| $191K | ﹤0.01% |
1,455
+7
| +0.5% | +$855 |
|
2752
Microvision
MVIS
$6.21M
| $191K | ﹤0.01% |
68,757
+3,234
| +5% | +$7.81K |
|
2753
NI Holdings
NODK
$310M
| $191K | ﹤0.01% |
10,688
+150
| +1% | +$2.59K |
|
|
NEOS
2754
DELISTED
Neos Therapeutics, Inc
NEOS
| $191K | ﹤0.01% |
20,909
+500
| +2% | +$3.8K |
|
|
I
2755
DELISTED
INTELSAT S. A.
I
| $190K | ﹤0.01% |
40,482
+790
| +2% | +$2.98K |
|
|
RARX
2756
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
| $190K | ﹤0.01% |
13,019
+185
| +1% | +$2.8K |
|
|
EPE
2757
DELISTED
EP Energy Corporation
EPE
| $190K | ﹤0.01% |
58,354
-182
| -0.3% | -$593 |
|
|
CORI
2758
DELISTED
Corium International, Inc.
CORI
| $190K | ﹤0.01% |
17,156
+941
| +6% | +$8.33K |
|
|
FNM
2759
DELISTED
FANNIE MAE
FNM
| $190K | ﹤0.01% |
63,500
| – | – |
|
|
FRE
2760
DELISTED
FREDDIE MAC D/B/A VOTING
FRE
| $190K | ﹤0.01% |
66,008
| – | – |
|
2761
Quantum Corp
QMCO
$419M
| $189K | ﹤0.01% |
1,547
+33
| +2% | +$4.42K |
|
2762
Twin Disc
TWIN
$329M
| $189K | ﹤0.01% |
10,135
+50
| +0.5% | +$867 |
|
|
KIN
2763
DELISTED
Kindred Biosciences, Inc.
KIN
| $189K | ﹤0.01% |
24,129
+1,280
| +6% | +$9.61K |
|
2764
Uranium Energy
UEC
$4.75B
| $187K | ﹤0.01% |
135,866
+3,810
| +3% | +$5.56K |
|
|
SYRS
2765
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $187K | ﹤0.01% |
1,273
+41
| +3% | +$7.71K |
|
2766
Escalade
ESCA
$273M
| $184K | ﹤0.01% |
13,555
-320
| -2% | -$4.01K |
|
2767
First Northwest Bancorp
FNWB
$109M
| $184K | ﹤0.01% |
10,763
-160
| -1% | -$2.54K |
|
2768
Ocular Therapeutix
OCUL
$1.79B
| $184K | ﹤0.01% |
29,835
+2,449
| +9% | +$15.8K |
|
2769
Prospect Capital
PSEC
$1.07B
| $181K | ﹤0.01% |
26,875
+84
| +0.3% | +$630 |
|
2770
Surgery Partners
SGRY
$2.01B
| $181K | ﹤0.01% |
17,485
+935
| +6% | +$13.4K |
|
|
ADXS
2771
DELISTED
Advaxis Inc
ADXS
| $181K | ﹤0.01% |
2,891
+57
| +2% | +$5.26K |
|
|
JAX
2772
DELISTED
J. Alexander's Holdings, Inc.
JAX
| $181K | ﹤0.01% |
15,629
-300
| -2% | -$3.1K |
|
|
PKD
2773
DELISTED
Parker Drilling Company
PKD
| $181K | ﹤0.01% |
10,946
-59
| -0.5% | -$1.08K |
|
|
KEG
2774
DELISTED
Key Energy Services, Inc. Common Stock
KEG
| $180K | ﹤0.01% |
13,641
+468
| +4% | +$7.13K |
|
2775
Sportsman's Warehouse
SPWH
$44.5M
| $179K | ﹤0.01% |
39,672
+440
| +1% | +$1.95K |
|
Similar funds
VAM
RhumbLine Advisers's Q3 2017 Portfolio in Review
As of Q3 2017, RhumbLine Advisers held 2,954 positions worth $46B, up 5% from $43.8B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Trading was light in Q3 2017: portfolio turnover was 2.6%. RhumbLine Advisers opened 28 new positions and exited 50, leaving the 2,954-position portfolio largely intact.
By sector, the portfolio is most concentrated in Financials at 17% of assets, up from 16% a quarter earlier, followed by Technology and Healthcare.
- RhumbLine Advisers's largest Q3 2017 buy was Baker Hughes: 750,985 shares worth $27.5M.
- RhumbLine Advisers added most to DuPont de Nemours in Q3 2017, an estimated $128M increase.
- RhumbLine Advisers's biggest Q3 2017 reduction was UnitedHealth, cutting an estimated $22.8M.
- RhumbLine Advisers fully exited Du Pont De Nemours E I in Q3 2017, selling an estimated $114M.
- RhumbLine Advisers's ten largest holdings make up 15% of its $46B portfolio in Q3 2017.
- RhumbLine Advisers opened 28 new positions and closed 50 in Q3 2017.
- RhumbLine Advisers's portfolio value rose 5% quarter-over-quarter to $46B.
Based on RhumbLine Advisers's 13F filing for Q3 2017, filed 6 Nov 2017.